medigraphic.com
Archivos de Medicina (Manizales)

2022, Number 2

<< Back Next >>

Arch Med 2022; 22 (2)

Characterization of patients with thrombocytopenia in a third level of complexity institution in Medellin, Colombia

Martínez-Sanchez LM, Hernández-Martínez A, Roldan-Tabares MD, Herrera-Almanza L, Villegas-Alzate JD, Calle-Estrada MC, Aristizábal-Hernández JJ, Vergara-Yanez D

Language: Spanish
References: 20
Page: 319-325
PDF size: 201.97 Kb.


ABSTRACT

Objective: characterize patients with thrombocytopenia in a third level-ofcomplexity institution in Medellín, Colombia. Materials and methods: a retrospective descriptive study was carried out, which included all patients with thrombocytopenia-related diagnosis treated in a level-of-complexity institution in the city of Medellin, during the January 2016 to December 2017-time period. A non-probabilistic sampling of consecutive cases was done. Results: 25 patients with thrombocytopenia were included. 80% of them (20) corresponded to children under 1 year of age and 20% (5) to people over 18 years of age, 52% (13) were male. Median in-hospital stay for adults was 10 days with a P25 of 5 and P75 of 39, for those aged ‹1 year, it was 32 (P25: 15 and P75: 53.25). 80% (20) of the patients were classified with unspecified thrombocytopenia, the remaining 20% (5) with secondary thrombocytopenia. The platelet counts in adults had a median of 95.000 cells/mm3 (P25: 67.000 and P75: 122.00) and in ‹1 year the median was 79.000 cells/mm3 (P25: 53.750 and P75: 109.750). Conclusions: thrombocyto penia was more common in children under 1 year and in the male sex, requiring longer hospital stays. Thrombocytopenia for both groups was classified as mild and according to its diagnosis as unspecified.


REFERENCES

  1. Lee EJ, Lee AI. Thrombocytopenia. Prim Care. 2016;43(4):543-557. DOI: 10.1016/j.pop.2016.07.008

  2. Fountain EM, Arepally GM. Etiology and complications of thrombocytopenia in hospitalized medical patients. JThromb Thrombolysis. 2017;43(4):429-436. DOI: 10.1007/s11239-016-1467-8.

  3. Nagalla S, Sarode R. Recent advances in understanding and management of acquired thrombocytopenia.F1000Res. 2018; 7:68-77. doi: 10.12688/f1000research.12309.1

  4. Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician. 2012;85(6):612-622. PMID: 22534274

  5. Akca S, Haji-Michael P, de Mendonça A, Suter P, Levi M, Vincent JL. Time course of platelet counts in criticallyill patients. Crit Care Med. 2002;30(4):753-756. DOI:10.1097/00003246-200204000-00005

  6. Crowther MA, Cook DJ, Meade MO, Griffith LE, Guyatt GH, Arnold DM, et al. Thrombocytopenia in medicalsurgicalcritically ill patients: prevalence, incidence, and risk factors. J Crit Care. 2005;20(4):348-353.DOI: 10.1016/j.jcrc.2005.09.008

  7. Thachil J, Warkentin TE. How do we approach thrombocytopenia in critically ill patients? Br J Haematol. 2017;177(1):27-38. doi: 10.1111/bjh.14482

  8. Greenberg EM. Thrombocytopenia: A Destruction of Platelets. J Infus Nurs. 2017;40(1):41-50.DOI:10.1097/NAN.0000000000000204

  9. Nandyal S, Shashikala P, Sahgal V. Study of thrombocytopenia in neonatal intensive care unit. IJPO. 2016;3(1);55-59. DOI: 10.5958/2394-6792.2016.00012.0

  10. Khalessi N, Khosravi N, Sanii S, Zareh Mehrjerdi F. The Prevalence and Risk Factors for Neonatal Thrombocytopeniaamong Newborns Admitted to Intensive Care Unit of Aliasghar Children’s Hospital. IJBC. 2013;2: 41-45

  11. Jeremiah Z, Oburu J. Pattern and prevalence of neonatal thrombocytopenia in Port Harcourt, Nigeria. Pathologyand Laboratory Medicine International. 2010; 2:27-31

  12. Beiner ME, Simchen MJ, Sivan E, Chetrit A, Kuint J, Schiff E. Risk Factors for Neonatal Thrombocytopenia inPreterm Infants. Am. J. Perinatol. 2003:20(1); 49-54.

  13. Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, et al. Second-line treatments in childrenwith immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. Am J Hematol. 2019;94(7):741-750. doi: 10.1002/ajh.25479

  14. Mahévas M, Moulis G, Andres E, Riviere E, Garzaro M, Crickx E, et al. Clinical characteristics, management andoutcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020;190(4): e224-e229. doi: 10.1111/bjh.17024

  15. Bolat F, Kılıç SÇ, Oflaz MB, Gülhan E, Kaya A, Güven AS, et al. The prevalence and outcomes of thrombocytopeniain a neonatal intensive care unit: a three-year report. Pediatr Hematol Oncol. 2012;29(8):710-720.DOI:10.3109/08880018.2012.725454

  16. Vaughan JL, Fourie J, Naidoo S, Subramony N, Wiggill T, Alli N. Prevalence and causes of thrombocytopenia inan academic state-sector laboratory in Soweto, Johannesburg, South Africa. S Afr Med J. 2015;105(3):215-219.DOI:10.7196/samj.8791

  17. Shalansky SJ, Verma AK, Levine M, Spinelli JJ, Dodek PM. Risk markers for thrombocytopenia in critically illpatients: a prospective analysis. Pharmacotherapy. 2002;22(7):803-813. DOI:10.1592/phco.22.11.803.33634

  18. Crespo EM, Oliveira GB, Honeycutt EF, Backer RC, Berger PB, Moliterno DJ et al. Evaluation and managementof thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The ComplicationsAfter Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J. 2009;157(4):651-657.DOI: 10.1016/j.ahj.2009.01.005

  19. Chao CJ, Shanbhag A, Chiang CC, Girardo ME, Seri AR, Khalid MU, et al. Baseline thrombocytopenia in acutecoronary syndrome: The lower, the worse. International Journal of Cardiology. 2021; 332: 1-7.doi: 10.1016/j.ijcard.2021.03.059.

  20. Venkata C, Kashyap R, Farmer JC, Afessa B. Thrombocytopenia in adult patients with sepsis: incidence, riskfactors, and its association with clinical outcome. J Intensive Care. 2013;1(1):9. DOI:10.1186/2052-0492-1-9.




2020     |     www.medigraphic.com